GIACONDA GETS EUROPEAN PATENT FOR IBS TREATMENT

Giaconda Limited Dec. 28 announced that the European Patent Office has granted its patent for the combination of olsalazine and colchicine for the treatment of irritable bowel syndrome (IBS). This patent is part of a wider Patent Cooperation Treaty application that has already been granted in Australia, South Africa and the U.S.

The issued patent provides further protection for Ibaconda, Giaconda's therapy for constipation predominant IBS. Ibaconda is a combination of two compounds, olsalazine and colchicine.

The grant of this patent allows Giaconda to certify the patent in Austria, Belgium, Cyprus, Switzerland and Liechtenstein, Germany, Denmark, Spain, Finland, France, the UK, Greece, Ireland, Italy, Luxembourg, Monaco, Netherlands, Portugal and Sweden.

Giaconda will begin proceedings to validate this patent in all of the above territories.